NEW YORK (360Dx) – The US Food and Drug Administration on Thursday announced it allowed Beckman Coulter to market ClearLLab Reagents for the detection of several leukemias and lymphomas.

The test, the agency said, is the first authorized by it for use with flow cytometry to detect the cancers. The reagents OK'd by the FDA are ClearLLab B1 (B-cell tube 1), ClearLLab B2 (B-cell tube 2), ClearLLab T1 (T-cell tube 1), ClearLLab T2 (T-cell tube 2), and ClearLLab M (myeloid tube).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.